Singapore markets closed

Straits Times Index
3,394.21
+17.02(+0.50%)
Nikkei
27,382.56
+19.81(+0.07%)
Hang Seng
22,688.90
+122.12(+0.54%)
FTSE 100
7,765.15
+4.04(+0.05%)
BTC-USD
23,455.54
+446.46(+1.94%)
CMC Crypto 200
526.66
+9.65(+1.87%)

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

4.6000

+0.0300

(+0.66%)

At close: 04:00PM EST

4.6600

+0.06

(+1.30%)

After hours:

04:01PM EST

Loading interactive chart…

Zacks
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Why Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season
Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.